Time to reclassify? The prognostic value of radiologic splenic vessel involvement in resectable pancreatic ductal adenocarcinoma of the body and tail: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1678 patients were analyzed.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This meta-analysis showed worse survival in patients with splenic vessel infiltration of PDAC. Therefore, SA and SV invasion may serve as indications for neoadjuvant therapy for resectable PDAC.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] The prognostic impact of radiographic splenic vessel involvement in pancreatic ductal adenocarcinoma (PDAC) of the body and tail remains controversial.
- p-value P = 0.007
- p-value P = 0.010
- 95% CI 1.13-2.44
- 연구 설계 meta-analysis
APA
Yao Z, Zhang J, et al. (2026). Time to reclassify? The prognostic value of radiologic splenic vessel involvement in resectable pancreatic ductal adenocarcinoma of the body and tail: a systematic review and meta-analysis.. International journal of surgery (London, England), 112(2), 5132-5140. https://doi.org/10.1097/JS9.0000000000003927
MLA
Yao Z, et al.. "Time to reclassify? The prognostic value of radiologic splenic vessel involvement in resectable pancreatic ductal adenocarcinoma of the body and tail: a systematic review and meta-analysis.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 5132-5140.
PMID
41287869 ↗
Abstract 한글 요약
[BACKGROUND] The prognostic impact of radiographic splenic vessel involvement in pancreatic ductal adenocarcinoma (PDAC) of the body and tail remains controversial.
[METHODS] A systematic search was performed using PubMed, Embase, the Cochrane Library, Web of Science, and Scopus in accordance with the PRISMA and AMASTAR guidelines. The primary outcome was 5-year overall survival (OS). Time-to-event method was used.
[RESULTS] Eight articles involving 1678 patients were analyzed. Patients with radiological splenic artery (SA) invasion had poorer OS than those without [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.14-2.29; P = 0.007]. Similarly, radiological splenic vein (SV) involvement was associated with significantly worse OS (HR 1.66, 95% CI 1.13-2.44; P = 0.010). Subgroup analyses for SA involvement, categorized by "abutment" and "encasement," showed an overall HR of 2.35 (95% CI 1.72-3.19; P < 0.00001), with HRs of 1.77 (95% CI 1.25-2.59; P = 0.001) for abutment and 3.03 (95% CI 2.20-4.17; P < 0.00001) for encasement, indicating a significant difference between subgroups ( P = 0.02). For SV involvement, the overall HR was 2.15 (95% CI 1.49-3.10; P < 0.001), with HRs of 1.66 (95% CI 0.97-2.84; P = 0.07) for abutment and 2.80 (95% CI 1.98-3.96; P < 0.0001) for encasement, showing no significant difference between subgroups ( P = 0.11).
[CONCLUSION] This meta-analysis showed worse survival in patients with splenic vessel infiltration of PDAC. Therefore, SA and SV invasion may serve as indications for neoadjuvant therapy for resectable PDAC.
[METHODS] A systematic search was performed using PubMed, Embase, the Cochrane Library, Web of Science, and Scopus in accordance with the PRISMA and AMASTAR guidelines. The primary outcome was 5-year overall survival (OS). Time-to-event method was used.
[RESULTS] Eight articles involving 1678 patients were analyzed. Patients with radiological splenic artery (SA) invasion had poorer OS than those without [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.14-2.29; P = 0.007]. Similarly, radiological splenic vein (SV) involvement was associated with significantly worse OS (HR 1.66, 95% CI 1.13-2.44; P = 0.010). Subgroup analyses for SA involvement, categorized by "abutment" and "encasement," showed an overall HR of 2.35 (95% CI 1.72-3.19; P < 0.00001), with HRs of 1.77 (95% CI 1.25-2.59; P = 0.001) for abutment and 3.03 (95% CI 2.20-4.17; P < 0.00001) for encasement, indicating a significant difference between subgroups ( P = 0.02). For SV involvement, the overall HR was 2.15 (95% CI 1.49-3.10; P < 0.001), with HRs of 1.66 (95% CI 0.97-2.84; P = 0.07) for abutment and 2.80 (95% CI 1.98-3.96; P < 0.0001) for encasement, showing no significant difference between subgroups ( P = 0.11).
[CONCLUSION] This meta-analysis showed worse survival in patients with splenic vessel infiltration of PDAC. Therefore, SA and SV invasion may serve as indications for neoadjuvant therapy for resectable PDAC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.
- Ubiquitin-conjugating Enzymes in Cancer.
- Dual-targeting CD133/PD-L1 CAR-T plus αPD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning.
- TCMNet: dynamic tanh enhanced 3D transformer with cascaded multiplicative fusion for pulmonary nodule detection.
- A label-aware diffusion model for weakly supervised deformable registration of multimodal MRI-TRUS in prostate cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.